Matches in Nanopublications for { ?s ?p "[The activation of this pathway explains the use of both VEGF and VEGF-receptor inhibitors (bevacizumab, sunitinib and sorafenib) in the therapy of advanced CCRCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion description "[The activation of this pathway explains the use of both VEGF and VEGF-receptor inhibitors (bevacizumab, sunitinib and sorafenib) in the therapy of advanced CCRCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.
- NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_assertion description "[The activation of this pathway explains the use of both VEGF and VEGF-receptor inhibitors (bevacizumab, sunitinib and sorafenib) in the therapy of advanced CCRCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP809737.RA1wTkaCxQxe7arGGLId0826WkFpri310JhFGIDpdw4bg130_provenance.